Table 1 Summary demographics and baseline characteristics of the trial subgroup of participants who received 3.75 µg CoVLP adjuvanted with AS03 (NCT04450004) and patients convalescing from COVID-19
Comparisons | Healthy individuals | Convalescent individuals Sampled 27–105 days post symptom onset | ||
|---|---|---|---|---|
3.75 µg CoVLP with AS03 adjuvant | Mild | Moderate | Severe | |
Subjects, n | 20 | 16 | 8 | 11 |
Sex, n (%) | ||||
Male | 5 (25.0) | 10 (62.5) | 2 (25.0) | 8 (72.7) |
Female | 15 (75.0) | 5 (31.3) | 6 (75.0) | 3 (27.3) |
Information non-available | 1 (6.2) | |||
Race, n (%) | ||||
White | 20 (100.0) | 7 (43.8) | 6 (75.0) | 5 (45.5) |
Black or African American | 0 (0.0) | 1 (6.3) | 0 (0.0) | 5 (45.5) |
Asian | 0 (0.0) | 4 (25.0) | 1 (12.5) | 0 (0.0) |
Ethnicity, n (%) | ||||
Hispanic/Latinx | 0 (0.0) | 2 (12.5) | 1 (12.5) | 1 (9.1) |
Age, years | ||||
Mean ± SD | 34.7 ± 9.1 | 42.7 ± 13.6 | 37.8 ± 13.0 | 51.9 ± 16.0 |
Median (range) | 36 (19–49) | 39 (20–66) | 40.5 (19–58) | 50.0 (28–82) |
